The University of Illinois at Chicago's Center for Clinical and Translational Science has selected six research projects to receive pilot grants in 2013.
[More]
A new analysis has provided a comprehensive comparison of scores designed to predict which women with oestrogen-receptor positive breast cancer are at high risk of recurrence beyond five years after diagnosis, and may benefit from prolonged endocrine treatment.
[More]
NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced results from two studies that are featured in oral presentations this week at IMPAKT Breast Cancer Conference.
[More]
Drinking coffee could decrease the risk of breast cancer recurring in patients taking the widely used drug Tamoxifen, a study at Lund University in Sweden has found. Patients who took the pill, along with two or more cups of coffee daily, reported less than half the rate of cancer recurrence, compared with their non-coffee drinking, Tamoxifen-taking counterparts.
[More]
Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary activities so that it might work on more aggressive breast cancer.
[More]
For women diagnosed with a form of breast cancer known as estrogen receptor positive (ER+) breast cancer, tamoxifen is an essential drug used in the treatment and prevention of recurring breast cancer.
[More]
Estrogen and progesterone receptors, and the gene HER2 - these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.
[More]
Researchers from Fox Chase Cancer Center have found that omega-3 fatty acids and their metabolite products slow or stop the proliferation, or growth in the number of cells, of triple-negative breast cancer cells more effectively than cells from luminal types of the disease.
[More]
One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course, according to a new study led by University of Michigan Comprehensive Cancer Center researchers.
[More]
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 175 national research and training grants totaling $79,073,250 for fiscal year 2013.
[More]
A team of international cancer researchers led by Dr. Mathieu Lupien at the Princess Margaret Cancer Centre, University Health Network, has identified the signalling pathway that is over-activated in estrogen receptor (ER)-positive breast cancer cells that are resistant to hormone therapies such as tamoxifen, aromatase inhibitors or fulvestrant.
[More]
Early trial findings suggest that copper depletion may promote tumor dormancy in patients at high risk for recurrent breast cancer.
[More]
Geneticists led by University of Utah Nobel Prize Laureate Mario R. Capecchi, Ph.D., have engineered mice that develop clear cell sarcoma (CCS), a significant step in better understanding how this rare and deadly soft tissue cancer arises. The mouse model also can potentially speed the development of drugs to target genes that must be activated for the cancer to form.
[More]
Women with a family history of breast or ovarian cancer are invited to meet with experts who will advise on preventing or delaying the disease. The University of Leicester's Genetics Education Networking for Innovation and Excellence (GENIE) will hold its third Lifestyle and Cancer Awareness Workshop on Saturday, February 23.
[More]
A new study has found that tamoxifen, a well-known breast cancer drug, can counteract some pathologic features in a mouse model of Duchenne muscular dystrophy (DMD). At present, no treatment is known to produce long-term improvement of the symptoms in boys with DMD, a debilitating muscular disorder that is characterized by progressive muscle wasting, respiratory and cardiac impairments, paralysis, and premature death.
[More]
The Dean of the Faculty of Science, Engineering and Computing at London's Kingston University has received a prestigious prize recognising her lifetime's work on drug metabolism.
[More]
Australian scientists have shown how a 'transcription factor' causes breast cancer to develop an aggressive subtype that lacks sensitivity to oestrogen and does not respond to anti-oestrogen therapies such as Tamoxifen and aromatase inhibitors.
[More]
For nearly a decade, breast cancer researchers studying the hormone therapy tamoxifen have been divided as to whether genetic differences in a liver enzyme affect the drug's effectiveness and the likelihood breast cancer will recur.
[More]
The HOPA Foundation Board of Directors is pleased to announce the recipients of the 2012 HOPA Foundation Research Award, Dr. Kamakshi Rao for her project Improving & Defining the Impact & Value of Pharmacists in Stem Cell Transplant, and to Dr. Quan Li, for his project, In Vitro Stability of Erlotinib, Lapatinib and Imatinib in Common Compounding Vehicles.
[More]
Younger women who wait at least 15 years after their first menstrual period to give birth to their first child may reduce their risk of an aggressive form of breast cancer by up to 60 percent, according to a Fred Hutchinson Cancer Research Center study.
[More]